STOCK TITAN

[Form 4] Dynavax Technologies Corporation Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4
Rhea-AI Filing Summary

Dynavax Technologies director Scott Myers purchased 3,800 shares of Dynavax Technologies Corp (DVAX) on 08/22/2025 at $10.82 per share in an open-market transaction. After the purchase he beneficially owns 35,004 shares, reported as direct ownership. The Form 4 was filed by a single reporting person and signed on 08/25/2025 by an attorney-in-fact. The filing discloses only this non-derivative common stock purchase; no options, dispositions, or additional transactions are reported.

Il direttore di Dynavax Technologies, Scott Myers, ha acquistato 3.800 azioni di Dynavax Technologies Corp (DVAX) il 08/22/2025 a $10,82 per azione in un'operazione di mercato aperto. Dopo l'acquisto possiede beneficiariamente 35.004 azioni, dichiarate come proprietà diretta. Il Modulo 4 è stato presentato da un unico soggetto segnalante e firmato il 08/25/2025 da un rappresentante munito di procura. La comunicazione riporta esclusivamente questo acquisto di azioni ordinarie non derivative; non sono segnalate opzioni, cessioni o altre operazioni.

El director de Dynavax Technologies, Scott Myers, compró 3.800 acciones de Dynavax Technologies Corp (DVAX) el 08/22/2025 a $10.82 por acción en una operación de mercado abierto. Tras la compra posee beneficiariamente 35.004 acciones, reportadas como propiedad directa. El Formulario 4 fue presentado por una sola persona informante y firmado el 08/25/2025 por un apoderado. La presentación divulga únicamente esta compra de acciones comunes no derivadas; no se informan opciones, disposiciones ni transacciones adicionales.

Dynavax Technologies의 이사 스콧 마이어스(Scott Myers)는 2025년 08/22에 공개시장 거래로 Dynavax Technologies Corp(DVAX) 주식 3,800주를 주당 $10.82에 매입했습니다. 매입 후 그는 직간접 소유로서 35,004주를 실질적으로 보유하고 있습니다(직접 소유로 보고). Form 4는 단일 보고자가 제출했으며 2025년 08/25에 대리인(위임자)에 의해 서명되었습니다. 해당 제출서류에는 이 비파생 보통주 매입만 공시되어 있으며, 옵션, 처분 또는 추가 거래는 보고되지 않았습니다.

Le directeur de Dynavax Technologies, Scott Myers, a acheté 3 800 actions de Dynavax Technologies Corp (DVAX) le 22/08/2025 au prix de 10,82 $ par action lors d'une opération sur le marché ouvert. Après cet achat, il détient à titre bénéficiaire 35 004 actions, déclarées en propriété directe. Le formulaire 4 a été déposé par une seule personne déclarante et signé le 25/08/2025 par un mandataire. Le dépôt divulgue uniquement cet achat d'actions ordinaires non dérivées; aucune option, cession ou transaction supplémentaire n'est signalée.

Dynavax Technologies-Direktor Scott Myers erwarb am 22.08.2025 im offenen Markt 3.800 Aktien von Dynavax Technologies Corp (DVAX) zum Preis von $10,82 je Aktie. Nach dem Kauf besitzt er wirtschaftlich 35.004 Aktien, die als direkte Beteiligung gemeldet werden. Das Formular 4 wurde von einer einzigen meldenden Person eingereicht und am 25.08.2025 von einem Bevollmächtigten unterzeichnet. Die Meldung offenbart nur diesen Kauf von nicht-derivativen Stammaktien; weder Optionen noch Veräußerungen oder weitere Transaktionen werden angegeben.

Positive
  • Insider purchase disclosed: Director Scott Myers acquired 3,800 shares on the open market at $10.82, demonstrating a non-derivative investment in the company.
  • Increased direct ownership: Holdings reported at 35,004 shares following the transaction, clearly stated on the Form 4.
Negative
  • None.

Insights

TL;DR: Director purchased a small block of shares on the open market, a factual disclosure without material earnings or governance change.

The report shows a straightforward open-market purchase of 3,800 shares at $10.82, increasing direct beneficial ownership to 35,004 shares. The size of the purchase relative to total outstanding shares is not provided, so its market impact cannot be determined from this filing alone. This is a routine Section 16 disclosure that signals an insider transaction but does not, by itself, indicate a material change in company fundamentals.

TL;DR: Standard Form 4 reporting of an insider buy; no governance actions or related-party changes disclosed.

The filing documents compliance with Section 16 reporting for a director's open-market purchase. It contains no amendments, no derivatives, and no indication of any change in the director's role or relationships with the issuer. From a governance perspective, the filing is routine and provides transparency on insider holdings without revealing additional governance risks or events.

Il direttore di Dynavax Technologies, Scott Myers, ha acquistato 3.800 azioni di Dynavax Technologies Corp (DVAX) il 08/22/2025 a $10,82 per azione in un'operazione di mercato aperto. Dopo l'acquisto possiede beneficiariamente 35.004 azioni, dichiarate come proprietà diretta. Il Modulo 4 è stato presentato da un unico soggetto segnalante e firmato il 08/25/2025 da un rappresentante munito di procura. La comunicazione riporta esclusivamente questo acquisto di azioni ordinarie non derivative; non sono segnalate opzioni, cessioni o altre operazioni.

El director de Dynavax Technologies, Scott Myers, compró 3.800 acciones de Dynavax Technologies Corp (DVAX) el 08/22/2025 a $10.82 por acción en una operación de mercado abierto. Tras la compra posee beneficiariamente 35.004 acciones, reportadas como propiedad directa. El Formulario 4 fue presentado por una sola persona informante y firmado el 08/25/2025 por un apoderado. La presentación divulga únicamente esta compra de acciones comunes no derivadas; no se informan opciones, disposiciones ni transacciones adicionales.

Dynavax Technologies의 이사 스콧 마이어스(Scott Myers)는 2025년 08/22에 공개시장 거래로 Dynavax Technologies Corp(DVAX) 주식 3,800주를 주당 $10.82에 매입했습니다. 매입 후 그는 직간접 소유로서 35,004주를 실질적으로 보유하고 있습니다(직접 소유로 보고). Form 4는 단일 보고자가 제출했으며 2025년 08/25에 대리인(위임자)에 의해 서명되었습니다. 해당 제출서류에는 이 비파생 보통주 매입만 공시되어 있으며, 옵션, 처분 또는 추가 거래는 보고되지 않았습니다.

Le directeur de Dynavax Technologies, Scott Myers, a acheté 3 800 actions de Dynavax Technologies Corp (DVAX) le 22/08/2025 au prix de 10,82 $ par action lors d'une opération sur le marché ouvert. Après cet achat, il détient à titre bénéficiaire 35 004 actions, déclarées en propriété directe. Le formulaire 4 a été déposé par une seule personne déclarante et signé le 25/08/2025 par un mandataire. Le dépôt divulgue uniquement cet achat d'actions ordinaires non dérivées; aucune option, cession ou transaction supplémentaire n'est signalée.

Dynavax Technologies-Direktor Scott Myers erwarb am 22.08.2025 im offenen Markt 3.800 Aktien von Dynavax Technologies Corp (DVAX) zum Preis von $10,82 je Aktie. Nach dem Kauf besitzt er wirtschaftlich 35.004 Aktien, die als direkte Beteiligung gemeldet werden. Das Formular 4 wurde von einer einzigen meldenden Person eingereicht und am 25.08.2025 von einem Bevollmächtigten unterzeichnet. Die Meldung offenbart nur diesen Kauf von nicht-derivativen Stammaktien; weder Optionen noch Veräußerungen oder weitere Transaktionen werden angegeben.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Myers Scott Dunseth

(Last) (First) (Middle)
C/O DYNAVAX TECHNOLOGIES
2100 POWELL STREET, SUITE 720

(Street)
EMERYVILLE CA 94608

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
DYNAVAX TECHNOLOGIES CORP [ DVAX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
08/22/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/22/2025 P 3,800(1) A $10.82 35,004 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Shares purchased on open market. All shares purchased at one price.
Remarks:
Scott Myers, by /s/ Trevor Dutcher, Attorney-in-Fact 08/25/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 filed for DVAX disclose?

The Form 4 discloses that director Scott Myers purchased 3,800 shares of Dynavax (DVAX) on 08/22/2025 at a price of $10.82 per share.

How many Dynavax shares does Scott Myers own after the transaction?

Following the reported purchase, Scott Myers beneficially owns 35,004 shares, held directly.

Was the purchase made on the open market or through a plan?

The filing states the shares were purchased on the open market and that all shares were purchased at one price.

Does the Form 4 report any derivative transactions or dispositions for DVAX?

No. The Form 4 only reports a non-derivative common stock acquisition; there are no derivatives or dispositions disclosed.

When was the Form 4 signed and filed?

The signature block shows the form was signed by an attorney-in-fact on 08/25/2025 and reports the transaction date as 08/22/2025.
Dynavax Technolo

NASDAQ:DVAX

DVAX Rankings

DVAX Latest News

DVAX Latest SEC Filings

DVAX Stock Data

1.23B
116.52M
0.6%
99.68%
12.36%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
EMERYVILLE